Sorrento Announces Full Enrollment of Phase I Study of Intranasal STI-9199 (COVISHIELD™ IN), a Potent Neutralization Antibody Against Omicron BA.2 and All Variants of Concern
The Phase I safety and pharmacokinetic study in 24 healthy volunteers has completed enrollment. The study is still blinded, but...